#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "mTOR-Related Brain Dysfunctions in Neuropsychiatric Disorders"
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Sandra Spalek"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/terminology
# --------------------------------------------------------------
DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/chebi-names.belns"
#DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/drugbank-names.belns"
#DEFINE NAMESPACE DOID           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/doid-names.belns"
#DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/ec-code.belns"
#DEFINE NAMESPACE FB             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/fb-names.belns"
DEFINE NAMESPACE HBP            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/export/hbp-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/hgnc-names.belns"
DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/hgnc.genefamily-names.belns"
#DEFINE NAMESPACE HP             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/hp-names.belns"
DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/go-names.belns"
#DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/interpro-names.belns"
DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/mesh-names.belns"
DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/mgi-names.belns"
#DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/mirbase-names.belns"
#DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/ncbigene.belns"
#DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/pfam-names.belns"
#DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
#DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
#DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
#DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
#DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
#DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
#DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
#DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
#DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
#DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
#DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
#DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############
SET Citation = {"PubMed", "30061532"}

# METH refers to methamphetamine

SET Evidence = "Remarkably, further investigation on the
autophagy pathway revealed that all these misfolded proteins are autophagy substrates depending
on mTOR activity"
bp(GO:autophagy) -> deg(p(MESH:Proteins,pmod(HBP:misfolded)))
act(p(HGNC:MTOR)) reg deg(p(MESH:Proteins,pmod(HBP:misfolded)))

SET Evidence = "In addition, most DLB patients show most features of AD (i.e., hyperphosphorylated tau deposits
and Abeta) to various extents"
# DLB: dementia with Lewy bodies
path(MESH:"Lewy Body Disease") -- p(HGNC:MAPT,pmod(HBP:hyperphosphorylation))
path(MESH:"Lewy Body Disease") -- a(CHEBI:"amyloid-beta")

SET Evidence = "Therefore, a common
pathogenesis underlying all these NDDs disorders has been linked to autophagy inhibition due
to mTOR hyperactivation"
# NDDs: neurodegenerative disorders
bp(GO:autophagy) -| path(MESH:"Neurodegenerative Diseases")
act(p(HGNC:MTOR)) neg bp(GO:autophagy)
act(p(HGNC:MTOR)) pos path(MESH:"Neurodegenerative Diseases")

SET Evidence = "For instance, an increased mTOR activity correlates with
accumulation of Abeta and hyperphosphorylated tau in AD brains"
SET MeSHAnatomy = "Brain"
SET MeSHDisease = "Alzheimer Disease"
act(p(HGNC:MTOR)) -> a(CHEBI:"amyloid-beta")
act(p(HGNC:MTOR)) -> p(HGNC:MAPT,pmod(HBP:hyperphosphorylation))
UNSET MeSHAnatomy
UNSET MeSHDisease

SET Evidence = "On the other hand, some
evidence indicates that suppressing mTOR activity ameliorates AD cognitive defects by decreasing
Abeta and tau pathology"
act(p(HGNC:MTOR)) -> path(MESH:"Alzheimer Disease")
act(p(HGNC:MTOR)) -> a(HBP:"Tau aggregates")
SET MeSHDisease = "Alzheimer Disease"
act(p(HGNC:MTOR)) -| bp(GO:cognition)
UNSET MeSHDisease

SET Evidence = "Again, rapamycin and rapalogs protect against toxicity produced by
a number of misfolded proteins encompassing alpha synuclein, TDP43, and hyperphosphorylated tau "
a(CHEBI:"sirolimus") -| act(p(HGNC:MTOR))
a(CHEBI:"sirolimus") -| p(HGNC:MAPT,pmod(HBP:hyperphosphorylation))
a(CHEBI:"sirolimus") -| p(HGNC:SNCA,pmod(HBP:misfolded))
a(CHEBI:"sirolimus") -| p(HGNC:TARDBP,pmod(HBP:misfolded))
a(CHEBI:"mTOR inhibitor") -| act(p(HGNC:MTOR))
a(CHEBI:"mTOR inhibitor") -| p(HGNC:MAPT,pmod(HBP:hyperphosphorylation))
a(CHEBI:"mTOR inhibitor") -| p(HGNC:SNCA,pmod(HBP:misfolded))
a(CHEBI:"mTOR inhibitor") -| p(HGNC:TARDBP,pmod(HBP:misfolded))

SET Evidence = "This is further supported by mounting evidence obtained in rodent models, which demonstrate that
rapamycin normalizes impaired social interactions and reverses behavioral defects"
a(CHEBI:"sirolimus") -> path(MESH:"Interpersonal Relations")
a(CHEBI:"sirolimus") -> bp(GO:behavior)

SET Evidence = "In schizophrenia, a progressive synaptic disorder is likely to promote neurodegeneration"
SET MeSHDisease = "Schizophrenia"
act(a(GO:"synapse")) -- path(HBP:Neurodegeneration)
UNSET MeSHDisease

SET Evidence = "As detailed in the following paragraph, METH exerts
disruptive effects on DA neurotransmission, which translate into abnormal stimulation of post-synaptic
DA receptors, mainly D1-type DA receptors (D1R), thus leading to non-canonical signaling cascades
sustaining behavioral alterations that overlap with schizophrenia-like symptoms (i.e., visual and
auditory hallucinations and delusions)"
# DA: dopamine
a(CHEBI:methamphetamine) -| bp(GO:"dopamine secretion, neurotransmission")
a(CHEBI:methamphetamine) -| act(p(HGNCGENEFAMILY:"Dopamine receptors"))
a(CHEBI:methamphetamine) -| act(p(HGNC:DRD1))
a(CHEBI:methamphetamine) -> bp(GO:"non-canonical Wnt signaling pathway")
a(CHEBI:methamphetamine) -> path(MESH:Hallucinations)
a(CHEBI:methamphetamine) -> path(MESH:Delusions)
path(MESH:Schizophrenia) -- path(MESH:Hallucinations)
path(MESH:Schizophrenia) -- path(MESH:Delusions)

SET Evidence = "Increased activity of D1R is considered as a
major determinant of neuropsychiatric alterations occurring in both METH models/abusers and
in schizophrenia"
path(MESH:Schizophrenia) pos act(p(HGNC:DRD1))

SET Evidence = "This is key, because abnormal stimulation of D1R and subsequent
signaling cascades were recently shown to produce an over-activation of mTOR and inhibition of the
autophagy machinery"
act(p(HGNC:DRD1)) -> act(p(HGNC:MTOR))
act(p(HGNC:DRD1)) -| bp(GO:autophagy)

SET Evidence = "In addition, several susceptibility genes for schizophrenia (e.g., DISC1,
NRG1/ErbB4, and CRMP2), which are involved in either pre-synaptic DA release or post-synaptic
D1R-related cascades, are similarly dysregulated by METH. Interestingly, they all converge on mTOR
signaling (see Section 6, Table 1)."
g(HGNC:DISC1) -- path(MESH:Schizophrenia)
g(HGNC:NRG1) -- path(MESH:Schizophrenia)
g(HGNC:DPYSL2) -- path(MESH:Schizophrenia)
a(CHEBI:methamphetamine) -| act(g(HGNC:DISC1))
a(CHEBI:methamphetamine) -| act(g(HGNC:NRG1))
a(CHEBI:methamphetamine) -| act(g(HGNC:DPYSL2))
act(g(HGNC:DISC1)) -- act(p(HGNC:MTOR))
act(g(HGNC:NRG1)) -- act(p(HGNC:MTOR))
act(g(HGNC:DPYSL2)) -- act(p(HGNC:MTOR))

SET Evidence = "In fact, mTOR-induced autophagy inhibition exacerbates the
ultrastructural effects of METH [126,134–136], while rapamycin administration reverts both behavioral
and morphological alterations induced by METH [137]."
act(p(HGNC:MTOR)) -| bp(GO:autophagy)
act(p(HGNC:MTOR)) -> act(a(CHEBI:methamphetamine))
bp(GO:autophagy) -| act(a(CHEBI:methamphetamine))
a(CHEBI:"sirolimus") -| act(a(CHEBI:methamphetamine))

SET Evidence = "In humans, the sensitizing
effects of prolonged chronic METH intake are considered a major determinant to the occurrence and
relapse of psychoses, which mirror those occurring in schizophrenic patients"
a(CHEBI:methamphetamine) -> path(MESH:"Psychoses, Substance-Induced")
path(MESH:Schizophrenia) -- path(MESH:"Psychotic Disorders")

SET Evidence = "Accordingly, clinical evidence points towards
an elevation of pre-synaptic DA synthesis and release as a key event for schizophrenia"
a(CHEBI:dopamine) pos path(MESH:Schizophrenia)
sec(a(CHEBI:dopamine)) -- path(MESH:Schizophrenia)

SET Evidence = "Likewise, the psychostimulant effects experienced by METH-addicted patients rely on increased
DA synthesis and massive DA release from nerve terminals within limbic areas as occurring in
the schizophrenic brain"
SET MeSHAnatomy = "Brain"
path(MESH:Schizophrenia) -> a(CHEBI:dopamine)
path(MESH:Schizophrenia) -> tloc(a(CHEBI:dopamine),fromLoc(MESH:"Nerve Endings"),toLoc(MESH:"Limbic System"))
UNSET MeSHAnatomy

SET Evidence = "Such an abnormal DA release produces peaks of extracellular
DA, which cannot be taken up within nerve terminals, because METH inhibits and reverts the
direction of the dopamine transporter (DAT)."
# DAT: SLC6A3
a(CHEBI:methamphetamine) -| act(p(HGNC:SLC6A3))
p(HGNC:SLC6A3) -> a(CHEBI:dopamine,loc(MESH:"Nerve Endings"))
a(CHEBI:methamphetamine) -| a(CHEBI:dopamine,loc(MESH:"Nerve Endings"))

SET Evidence = "In line with this, recent studies suggest that DAT
expression is significantly reduced in the midbrain of postmortem schizophrenic samples [150],
which is reminiscent of the METH-addicted brain [151,152]."
SET MeSHAnatomy = "Mesencephalon"
path(MESH:Schizophrenia) -| p(HGNC:SLC6A3)
SET MeSHAnatomy = "Brain"
a(CHEBI:methamphetamine) -| p(HGNC:SLC6A3)
UNSET MeSHAnatomy

SET Evidence = "Likewise, rapamycin was found to be beneficial for ameliorating psychotic symptoms"
a(CHEBI:"sirolimus") -| path(MESH:"Psychotic Disorders")

SET Evidence = "The relevance of autophagy for sustaining these mTOR-induced
effects is confirmed by drugs inducing autophagy independently of mTOR activation"
# METH-induced behavioral sensitization
bp(GO:autophagy) reg act(p(HGNC:MTOR))

SET Evidence = "In fact, lithium
is able to delay METH-induced sensitization, while being a powerful treatment in schizophrenia"
a(CHEBI:"lithium(1+)") -| act(p(HGNC:MTOR))
a(CHEBI:"lithium(1+)") -| path(MESH:Schizophrenia)

SET Evidence = "Noteworthy, genetic ablation of autophagy was shown
to produce an extremely powerful DA release upon electrical stimuli, suggesting that autophagy is
key to restrain DA release both upon basal neural activity and mostly after rapamycin-induced
autophagy"
bp(GO:autophagy) -| sec(a(CHEBI:dopamine))
a(CHEBI:"sirolimus") -> bp(GO:autophagy)

SET Evidence = "These findings strongly suggest that an autophagy dysfunction acts both at
pre- and post-synaptic level to alter DA neurotransmission during both METH administration
and schizophrenia (Figure 2)"
a(CHEBI:methamphetamine) -- bp(GO:"dopamine secretion, neurotransmission")
a(CHEBI:methamphetamine) -| sec(a(CHEBI:dopamine))
SET MeSHDisease = "Schizophrenia"
bp(GO:autophagy) -- bp(GO:"dopamine secretion, neurotransmission")
bp(GO:autophagy) -| sec(a(CHEBI:dopamine))
UNSET MeSHDisease

SET Evidence = "This confirms our previous studies showing that both genetic and
pharmacological autophagy inhibition worsen the effects of METH administration"
bp(GO:autophagy) -| act(a(CHEBI:methamphetamine))

SET Evidence = "In line with this, METH produces ultrastructural alterations reflecting dysfunctional
autophagy flux, which are DA-dependent"
a(CHEBI:methamphetamine) -| bp(GO:autophagy)
a(CHEBI:dopamine) reg bp(GO:autophagy)

SET Evidence = "In fact, METH produces a massive increase of endogenous
intra-cytosolic DA levels by inhibiting and reverting the direction of the vesicular monoamine
transporter type 2 (VMAT-2), thus disrupting the physiological storage of DA"
a(CHEBI:methamphetamine) -> a(CHEBI:dopamine,loc(GO:cytosol))
a(CHEBI:methamphetamine) -| act(p(HGNC:SLC18A2))
p(HGNC:SLC18A2) -- a(CHEBI:dopamine)

SET Evidence = "A reduction in
VMAT-2 gene expression and protein levels in DA neurons occurs in both METH models and
schizophrenic patients, marking quite impressively the overlap between these disorders"
SET Cell = "dopaminergic neuron"
path(MESH:Schizophrenia) neg p(HGNC:SLC18A2)
a(CHEBI:methamphetamine) neg p(HGNC:SLC18A2)
UNSET Cell

SET Evidence = "It is worth mentioning that freely diffusible intra-cytosolic DA can readily undergo auto-oxidation
and produce a cascade of oxidative-related damage, which is bound to the neurotoxic effects of
high doses of METH"
a(CHEBI:dopamine) -> bp(GO:"response to oxidative stress")
a(CHEBI:methamphetamine) -> bp(GO:"response to oxidative stress")

SET Evidence = "Beyond METH,
redox-related changes that result from an imbalance between reactive oxygen species (ROS)
production and ROS clearance are implicated in schizophrenia"
a(CHEBI:"reactive oxygen species") -- path(MESH:Schizophrenia)

SET Evidence = "In addition, the occurrence of alpha synuclein gene (SNCA) polymorphisms is associated with human METH psychosis [166]."
p(HGNC:SNCA,var("?")) -- path(MESH:"Psychotic Disorders")
path(MESH:Schizophrenia) -> path(MESH:"Psychotic Disorders")

SET Evidence = "In addition, cytoskeletal derangement appears as a prominent feature of the ultrastructural pathology
of schizophrenia"
path(MESH:Schizophrenia) neg bp(GO:"cytoskeleton organization")

SET Evidence = "Cytoskeleton organization and dynamics depend on the fine control of
microtubule assembly, which relies on the interaction of microtubules with a specific class of proteins
known as microtubule-associated protein (MAP)."
bp(GO:"microtubule polymerization") -> bp(GO:"cytoskeleton organization")
complex(a(MESH:"Microtubule-Associated Proteins"),a(GO:microtubule)) -> bp(GO:"microtubule polymerization")

SET Evidence = "Among various
identified MAPs, microtubule-associated protein 2 (MAP2), which belongs to the MAP2/Tau family,
is enriched in the brain and especially in dendrites, where it contributes to microtubule stabilization
and overall dendritic architecture."
SET MeSHAnatomy = {"Brain","Dendrites"}
p(HGNC:MAP2) -> a(GO:microtubule)
p(HGNC:MAP2) -> bp(GO:"dendritic spine organization")
UNSET MeSHAnatomy

SET Evidence = "Alterations in MAP2 immunoreactivity within the subiculum,
entorhinal cortex, hippocampus, and prefrontal cortex have been suggested as the primary array
of cytoskeletal abnormalities, which in turn result in impaired neurotransmission observed in
schizophrenia"
SET MeSHAnatomy = {"Hippocampus","Entorhinal Cortex","Prefrontal Cortex"}
p(HGNC:MAP2) -> bp(GO:"cytoskeleton organization")
bp(GO:"cytoskeleton organization") -> bp(GO:"neuron-neuron synaptic transmission")
path(MESH:Schizophrenia) neg bp(GO:"neuron-neuron synaptic transmission")
UNSET MeSHAnatomy

SET Evidence = "Notably, a marked reduction in MAP2 immunoreactivity, along with a
decrease in dendritic arbor, is reported in the primary auditory cortex (BA41) of schizophrenic
subjects compared with healthy controls"
SET MeSHAnatomy = "Auditory Cortex"
path(MESH:Schizophrenia) -| p(HGNC:MAP2)
path(MESH:Schizophrenia) -| a(GO:dendrite)
UNSET MeSHAnatomy

SET Evidence = "Moreover, pathological deposition
of hyperphosphorylated MAP-tau (MAPT), which is the hallmark of several neurodegenerative
disorders such as AD and frontotemporal dementia (FTD), has been described in elderly subjects with
schizophrenia"
path(MESH:"Alzheimer Disease") pos p(HGNC:MAPT,pmod(HBP:hyperphosphorylation))
path(MESH:"Frontotemporal Dementia") pos p(HGNC:MAPT,pmod(HBP:hyperphosphorylation))
path(MESH:Schizophrenia) pos p(HGNC:MAPT,pmod(HBP:hyperphosphorylation))

SET Evidence = "Momeni and colleagues (2010) recently reported
two relatives with an early age at onset (27 and 29 years) of schizophrenic symptoms showing a marked
neuronal tau deposition, as confirmed at pathological examination"
path(MESH:Schizophrenia) -> p(HGNC:MAPT,loc(MESH:Neurons))

SET Evidence = "Notably, post-mortem analysis performed in the prefrontal cortex of schizophrenic patients revealed
oligodendrocyte ultrastructural abnormalities"
SET MeSHAnatomy = "Prefrontal Cortex"
path(MESH:Schizophrenia) -| bp(GO:"oligodendrocyte development")
UNSET MeSHAnatomy

SET Evidence = "Remarkably, a very recent neuropathological examination provided evidence for
TDP-43-positive cytosolic inclusions and dystrophic neurites in the brain of a patient diagnosed
with FTLD presenting brief psychotic episodes and catatonia, which is a syndrome related to
schizophrenia"
SET MeSHAnatomy = "Brain"
path(MESH:"Frontotemporal Lobar Degeneration") -- path(MESH:"Psychotic Disorders")
path(MESH:"Frontotemporal Lobar Degeneration") -- path(MESH:Catatonia)
p(HGNC:TARDBP,loc(GO:"inclusion body")) -- path(MESH:"Frontotemporal Lobar Degeneration")
p(HGNC:TARDBP,loc(HBP:"dystrophic neurite")) -- path(MESH:"Frontotemporal Lobar Degeneration")
path(MESH:Catatonia) -- path(MESH:Schizophrenia)
UNSET MeSHAnatomy

SET Evidence = "Preliminary in vitro studies demonstrated that two proteins, namely DISC1
and dysbindin-1, which are encoded by two susceptibility genes for schizophrenia, can form insoluble
protein aggregates that are reminiscent of those occurring in neurodegenerative disorders"
p(HGNC:DISC1) -- path(MESH:Schizophrenia)
p(HGNC:DISC1) -> a(HBP:"protein aggregates")
p(HGNC:DTNBP1) -- path(MESH:Schizophrenia)
p(HGNC:DTNBP1) -> a(HBP:"protein aggregates")

SET Evidence = "Intriguingly, the interactome analysis of both DISC1, dysbindin-1, and CRMP2, which is another
susceptibility gene for schizophrenia, revealed common protein interactions with microtubules, actin
cytoskeleton, and proteins involved in intracellular transport"
p(HGNC:DISC1) -- path(MESH:Schizophrenia)
complex(p(HGNC:DISC1),a(GO:microtubule))
complex(p(HGNC:DISC1),a(GO:"actin cytoskeleton"))
p(HGNC:DTNBP1) -- path(MESH:Schizophrenia)
complex(p(HGNC:DTNBP1),a(GO:microtubule))
complex(p(HGNC:DTNBP1),a(GO:"actin cytoskeleton"))
p(HGNC:DPYSL2) -- path(MESH:Schizophrenia)
complex(p(HGNC:DPYSL2),a(GO:microtubule))
complex(p(HGNC:DPYSL2),a(GO:"actin cytoskeleton"))

SET Evidence = "In particular, CRMP2 is
a cytosolic protein enriched in the CNS, which has been implicated in microtubule stabilization,
and thus in the regulation of cytoskeletal dynamics and vesicle trafficking"
p(HGNC:DTNBP1) -- a(GO:"microtubule cytoskeleton")
p(HGNC:DTNBP1) -- act(a(GO:cytoskeleton))
p(HGNC:DTNBP1) -- bp(GO:"synaptic vesicle transport")

SET Evidence = "The biological implication behind an impairment of microtubule dynamics is confirmed
in post-mortem schizophrenic brain samples, as well as in mouse models of schizophrenia, where
mTOR-dependent autophagy dysfunction is accompanied by an altered gene expression and protein
levels of the microtubule-associated protein 6 (MAP6)"
SET MeSHAnatomy = "Brain"
SET MeSHDisease = "Schizophrenia"
path(MESH:Schizophrenia) neg act(a(GO:microtubule))
p(HGNC:MTOR) -| bp(GO:autophagy)
act(p(HGNC:MTOR)) -- p(HGNC:MAP6)
UNSET MeSHAnatomy
UNSET MeSHDisease

SET Evidence = "This is the case of the disrupted in schizophrenia 1 (DISC1)
gene, a schizophrenia-related gene, originally discovered in a large Scottish family with a
high incidence of psychiatric symptoms"
g(HGNC:DISC1) -- path(MESH:Schizophrenia)

SET Evidence = "This gene encodes for the DISC1 ubiquitous
protein, which is implicated in neurogenesis, neuronal migration, axon/dendrite, and synapse
formation"
p(HGNC:DISC1) -- bp(MESH:Neurogenesis)
p(HGNC:DISC1) -- bp(GO:"neuron migration")
p(HGNC:DISC1) -- bp(GO:"axon development")
p(HGNC:DISC1) -- a(GO:dendrite)
p(HGNC:DISC1) -- a(GO:synapse)

SET Evidence = "Remarkably, DISC1 plays a key role in DA neurotransmission"
p(HGNC:DISC1) -- bp(GO:"dopamine secretion, neurotransmission")

SET Evidence = "In line with this, experimental models of DISC1 deficiency treated with METH show a significant potentiation
of DA release, along with increased expression of D1R in the ventral striatum when compared with controls"
a(CHEBI:methamphetamine) -- sec(a(CHEBI:dopamine))
a(CHEBI:methamphetamine) -- p(HGNC:DRD1)

SET Evidence = "In addition, these findings strongly suggest that DISC1 alterations may
increase the risk of schizophrenia by dysregulating DA release"
p(HGNC:DISC1,var("?")) -> path(MESH:Schizophrenia)
p(HGNC:DISC1,var("?")) -| sec(a(CHEBI:dopamine))

SET Evidence = "In particular, DISC1 acts by blocking
KIAA1212, an Akt-binding partner, which directly interacts with Akt and strengthens the activation of
this kinase, which represents a major mediator of the mTOR pathway."
p(HGNC:DISC1) -| act(p(HGNC:CCDC88A))
complex(p(HGNC:CCDC88A),p(FPLX:AKT)) -> act(p(FPLX:AKT))
p(FPLX:AKT) reg act(p(HGNC:MTOR))

SET Evidence = "Therefore, the binding between
DISC1 and KIAA1212 prevents KIAA1212-dependent Akt activation (Figure 3)."
complex(p(HGNC:CCDC88A),p(HGNC:DISC1)) -| act(p(FPLX:AKT))
p(HGNC:CCDC88A) -> act(p(FPLX:AKT))

SET Evidence = "This decreases Akt
activity, which in turn dampens mTOR signaling"
# this: binding between DISC1 and KIAA1212
complex(p(HGNC:CCDC88A),p(HGNC:DISC1)) -| act(p(FPLX:AKT))
complex(p(HGNC:CCDC88A),p(HGNC:DISC1)) -| act(p(HGNC:MTOR))

SET Evidence = "Therefore, disruption of DISC1 activity,
due to genetic rearrangements (i.e., balanced (1;11) (q42;q14) chromosomal translocation) or
missense mutations, produces schizophrenic-like behavior, which is bound to enhanced Akt activity,
over-activation of mTOR signaling, and depressed autophagy"
p(HGNC:DISC1,var("?")) -> path(MESH:Schizophrenia)
p(HGNC:DISC1,var("?")) -> act(p(FPLX:AKT))
p(HGNC:DISC1,var("?")) -> act(p(HGNC:MTOR))
p(HGNC:DISC1,var("?")) -| bp(GO:autophagy)

SET Evidence = "Likewise, administration of
either D1R agonists or METH enhances Akt activity and over-activates mTOR signaling"
act(p(HGNC:DRD1)) -> act(p(FPLX:AKT))
act(p(HGNC:DRD1)) -> act(p(HGNC:MTOR))
a(CHEBI:methamphetamine) -> act(p(FPLX:AKT))
a(CHEBI:methamphetamine) -> act(p(HGNC:MTOR))

SET Evidence = "Again, an impaired
Akt signaling, achieved by neuronal deletion of rictor, a key regulatory subunit of mTORC2,
contributes to schizophrenia-like phenotypes in rictor-null (KO) mice"
SET Species = "10090"
p(MGI:Rictor) -| bp(GO:"protein kinase B signaling")
bp(GO:"protein kinase B signaling") -- path(MESH:Schizophrenia)
UNSET Species

SET Evidence = "Dysregulation in Akt
signaling and altered Akt protein levels were found in the frontal cortex and hippocampus of
post-mortem brain samples from individuals affected by schizophrenia"
SET MeSHAnatomy = {"Hippocampus","Prefrontal Cortex"}
path(MESH:Schizophrenia) -| p(FPLX:AKT)
path(MESH:Schizophrenia) -| bp(GO:"protein kinase B signaling")
UNSET MeSHAnatomy

SET Evidence = "Furthermore, genetic linkage and association studies led to the identification of two additional
susceptibility factors related to schizophrenia, such as neuregulin-1 (NRG1) and its receptor ErbB4"
p(HGNC:NRG1) -- path(MESH:Schizophrenia)
p(HGNC:ERBB4) -- path(MESH:Schizophrenia)

SET Evidence = "In particular, NRG1, which is mostly
involved in regulating neurodevelopment and neurotransmission, acts by binding ErbB4, a type I
transmembrane receptor tyrosine kinase belonging to the family of ErbB proteins, which contain a
binding site for PI3K kinase, an AKT upstream effector, in the C-terminal cytoplasmic tail (CYT)"
complex(p(HGNC:NRG1),p(HGNC:ERBB4)) reg bp(GO:"generation of neurons")
complex(p(HGNC:NRG1),p(HGNC:ERBB4)) reg bp(GO:"neuron-neuron synaptic transmission")

SET Evidence = "The binding between ErbB4 and PI3K activates this latter kinase, which in turn can phosphorylate
and activate its downstream target Akt"
complex(p(FPLX:PI3K),p(HGNC:ERBB4)) -> act(p(FPLX:PI3K))
kin(p(FPLX:PI3K)) -> p(FPLX:AKT,pmod(Ph))
act(p(FPLX:PI3K)) -> act(p(FPLX:AKT))

SET Evidence = "Moreover, it has been demonstrated that NRG1 also regulates DISC1 expression [230], thus further worsening the
aberrancy of the Akt–mTOR pathway and the pathogenesis of schizophrenia and related behaviors."
p(HGNC:NRG1) reg p(HGNC:DISC1)
p(HGNC:NRG1) -- bp(GO:"protein kinase B signaling")
p(HGNC:NRG1) -- act(p(HGNC:MTOR))
p(HGNC:NRG1) -- path(MESH:Schizophrenia)
act(p(HGNC:MTOR)) -- path(MESH:Schizophrenia)
bp(GO:"protein kinase B signaling") -- path(MESH:Schizophrenia)

SET Evidence = "Noteworthy, NRG1/ErbB4 signaling plays a key role in DA-related behaviors by increasing DA release
within the hippocampus, striatum, and prefrontal cortex"
SET MeSHAnatomy = {"Hippocampus","Prefrontal Cortex","Corpus Striatum"}
act(complex(p(HGNC:NRG1),p(HGNC:ERBB4))) -> sec(a(CHEBI:dopamine))
UNSET MeSHAnatomy

SET Evidence = "Another identified susceptibility gene for schizophrenia is the dihydropyrimidinase-like
2 (DPYSL2) gene"
g(HGNC:DPYSL2) -- path(MESH:Schizophrenia)

SET Evidence = "This gene is located on chromosome 8p21 and it encodes the cytosolic
microtubule-associated protein CRMP2 (collapsin response mediator protein-2), which is highly
expressed in the CNS and plays a role in axonal growth"
# this gene: DPYSL2
g(HGNC:DPYSL2) -> p(HGNC:DPYSL2)
p(HGNC:DPYSL2) -- bp(GO:"axon development")

SET Evidence = "In line with this, the dendritic
spine-regulating activity of CRMP2 is under the control of the cyclin-dependent kinase 5 (CDK5)"
p(HGNC:CDK5) reg p(HGNC:DPYSL2)
p(HGNC:DPYSL2) reg a(GO:"dendritic spine")

SET Evidence = "Both administration of amphetamines and stimulation of D1R induce a significant increase of CDK5
gene expression and protein levels, which, at molecular level, associates with increased dendritic spine
density and hyper-phosphorylation of the cytoskeletal tau protein"
act(p(HGNC:DRD1)) -> g(HGNC:CDK5)
act(p(HGNC:DRD1)) -> p(HGNC:CDK5)
a(CHEBI:amphetamine) -> g(HGNC:CDK5)
a(CHEBI:amphetamine) -> p(HGNC:CDK5)
p(HGNC:CDK5) pos a(GO:"dendritic spine")
p(HGNC:CDK5) pos p(HGNC:MAPT,pmod(HBP:hyperphosphorylation))

SET Evidence = "In detail, the activation
of CDK5 by D1R occurs via proteolysis of p35, the binding partner of CDK5"
# p35: CDK5R1
p(HGNC:DRD1) -> p(HGNC:CDK5)
p(HGNC:CDK5R1,frag("?")) -> act(p(HGNC:CDK5))
complex(p(HGNC:CDK5R1),p(HGNC:CDK5))

SET Evidence = "Remarkably, the marked
reduction of p35 levels in schizophrenic brains, which mirrors enhanced CDK5 activity [247], suggests
a role for CDK5-CRMP2-dependent alterations of cytoskeleton architecture and psychiatric behavior"
SET MeSHAnatomy = "Brain"
path(MESH:Schizophrenia) neg p(HGNC:CDK5R1)
path(MESH:Schizophrenia) pos act(p(HGNC:CDK5))
p(HGNC:CDK5R1) neg act(p(HGNC:CDK5))
complex(p(HGNC:DPYSL2),p(HGNC:CDK5)) -- bp(GO:"cytoskeleton organization")
complex(p(HGNC:DPYSL2),p(HGNC:CDK5)) -- path(MESH:"Mental Disorders")
UNSET MeSHAnatomy

SET Evidence = "Remarkably, the identification of rare genetic variants of ULK1 in a cohort of schizophrenic patients by
means of exome sequence analysis strengthens the idea of a key role of both disrupted mTOR signaling
and autophagy in the pathophysiology and susceptibility to schizophrenia"
p(HGNC:ULK1,var("?")) -- path(MESH:Schizophrenia)
path(MESH:Schizophrenia) neg act(p(HGNC:MTOR))
path(MESH:Schizophrenia) neg bp(GO:autophagy)

SET Evidence = "In particular, at BA 22, the vast majority of abnormally expressed genes
referred to key autophagy genes (i.e., BECN1, ULK2, ATG3), which were significantly down-regulated
compared with controls"
# downregulation in Schizophrenia
# BA 22: Broadman area 22 (associated with is associated with positive symptoms, mainly auditory-verbal hallucinations or “hearing voices”)
p(HGNC:BECN1) -- bp(GO:autophagy)
path(MESH:Schizophrenia) -| p(HGNC:BECN1)
p(HGNC:ULK2) -- bp(GO:autophagy)
path(MESH:Schizophrenia) -| p(HGNC:ULK2)
p(HGNC:ATG3) -- bp(GO:autophagy)
path(MESH:Schizophrenia) -| p(HGNC:ATG3)

SET Evidence = "A few months later, another transcriptomic study reported a BA
22-specific down-regulation in several autophagy-related genes, thus strengthening the link between
impaired autophagy and schizophrenia positive symptoms"
# positive symptoms: mainly auditory-verbal hallucinations or “hearing voices”
path(MESH:Schizophrenia) neg bp(GO:autophagy)
path(MESH:Hallucinations) neg bp(GO:autophagy)

SET Evidence = "Later on,
further analysis reported a disruption of the autophagy pathway also in the hippocampus of
post-mortem schizophrenic patients"
SET MeSHAnatomy = "Hippocampus"
path(MESH:Schizophrenia) neg bp(GO:autophagy)
UNSET MeSHAnatomy

SET Evidence = "In detail, the analysis of mRNA expression of a key
protein for autophagy initiation, namely beclin1, revealed a significant region-specific reduction in
hippocampal samples from 12 schizophrenic patients compared with 12 age-matched healthy controls."
SET MeSHAnatomy = "Hippocampus"
path(MESH:Schizophrenia) -| p(HGNC:BECN1)
UNSET MeSHAnatomy

SET Evidence = "ADNP is an essential protein for brain development and it has
been shown to physically interact with a key protein in autophagosome biogenesis and maturation,
namely LC3"
p(HGNC:ADNP) -> bp(GO:"brain development")
complex(p(HGNC:ADNP),p(HGNC:MAP1LC3A))
p(HGNC:MAP1LC3A) -> bp(GO:"autophagosome assembly")
p(HGNC:MAP1LC3A) -> bp(GO:"autophagosome maturation")

SET Evidence = "A reduction of ADNP and its homologous
protein, ADNP2, is observed in schizophrenic patients [254], and it is recapitulated in Map6-deficient
(Map6+/-) mice, another transgenic model of schizophrenia"
path(MESH:Schizophrenia) -| p(HGNC:ADNP)
path(MESH:Schizophrenia) -| p(HGNC:ADNP2)

SET Evidence = "Immuno-histochemical analysis
showed a three-fold decrease in the number of beclin1-positive cells in Map6+/- mice"
# Map6+/- mice, transgenic model of schizophrenia
path(MESH:Schizophrenia)  -| p(HGNC:BECN1)

SET Evidence = "On the other hand, chronic treatment with an eight-amino-acid peptide snippet from ADNP (NAP),
also known as davunetide, restored both Beclin1 and ADNP mRNA levels along with ADNP-LC3
interaction, thus providing neuroprotection while ameliorating schizophrenic-like behavioral and
cognitive deficits in Map6+/- mice"
SET MeSHDisease = "Schizophrenia"
a(PUBCHEM:9832404) -> r(HGNC:BECN1)
a(PUBCHEM:9832404) -> r(HGNC:ADNP)
a(PUBCHEM:9832404) -> complex(p(HGNC:ADNP),p(HGNC:MAP1LC3A))
a(PUBCHEM:9832404) -| bp(GO:"neuron death")
a(PUBCHEM:9832404) -> bp(GO:cognition)
a(PUBCHEM:9832404) -| path(MESH:"Mental Disorders")
UNSET MeSHDisease

SET Evidence = "These pieces
of evidence corroborate findings showing that several autophagy inducers, such as lithium, rapamycin,
and Food and Drug Administration (FDA) approved antipsychotic drugs are effective to treat
psychosis including schizophrenia"
a(CHEBI:"lithium(1+)") -| path(MESH:Schizophrenia)
a(CHEBI:"lithium(1+)") -| path(MESH:"Psychotic Disorders")
a(CHEBI:"sirolimus") -| path(MESH:Schizophrenia)
a(CHEBI:"sirolimus") -| path(MESH:"Psychotic Disorders")
a(MESH:"Antipsychotic Agents") -| path(MESH:Schizophrenia)
a(MESH:"Antipsychotic Agents") -| path(MESH:"Psychotic Disorders")

SET Evidence = "Notably, high-throughput image-based
screens performed by Zhang et al. (2007) [60] on a human glioblastoma H4 cell line expressing
human LC3 coupled with green fluorescent protein (GFP) led us to disclose that three typical
antipsychotic drugs (fluspirilene, trifluoperazine, and pimozide) are effective autophagy inducers."
a(PUBCHEM:3396) -> bp(GO:autophagy)
a(CHEBI:trifluoperazine) -> bp(GO:autophagy)
a(CHEBI:pimozide) -> bp(GO:autophagy)

SET Evidence = "In particular, pimozide provides an mTOR-independent autophagy induction, because it directly
activates AMPK1, which in turn promotes autophagy through the phosphorylation of ULK1"
# AMPK1 is PRKAA1
a(CHEBI:pimozide) -> act(p(HGNC:PRKAA1))
act(p(HGNC:PRKAA1)) -> p(HGNC:ULK1,pmod(Ph))
p(HGNC:ULK1,pmod(Ph)) -> bp(GO:autophagy)

SET Evidence = "In contrast, chlorpromazine, which is a typical antipsychotic agent, induces autophagy by inhibiting
the Akt/mTOR pathway"
a(CHEBI:chlorpromazine) -> bp(GO:autophagy)
a(CHEBI:chlorpromazine) -| bp(GO:"protein kinase B signaling")
a(CHEBI:chlorpromazine) -| act(p(HGNC:MTOR))

SET Evidence = "Recently, in vitro studies on the effects of second-generation, atypical
antipsychotics demonstrated that sertindole and clozapine are potent autophagy inducers in both
neuronal and non-neuronal cell lines"
a(CHEBI:sertindole) -> bp(GO:autophagy)
a(CHEBI:clozapine) -> bp(GO:autophagy)

SET Evidence = "Similar to pimozide, clozapine activates the autophagy
process via the AMPK–ULK1–Beclin1 pathway, as evidenced by increased levels of autophagy markers
(i.e., LC3-II and Atg5–Atg12 conjugate); increased phosphorylation of AMPK and its downstream
substrates, namely ULK1 and beclin1; and an increased number of autophagosomes in the frontal cortex
in clozapine-treated rats"
a(CHEBI:clozapine) -> bp(GO:autophagy)
a(CHEBI:clozapine) -> p(HGNC:PRKAA1,pmod(Ph)))
a(CHEBI:clozapine) -> p(HGNC:ULK1,pmod(Ph))
a(CHEBI:clozapine) -> p(HGNC:BECN1,pmod(Ph))
SET MeSHAnatomy = "Frontal Lobe"
a(CHEBI:clozapine) -> a(GO:autophagosome)

SET Evidence = "For instance, the increase
in autophagy flux induced by pimozide occurs along with a depression of phosphorylated tau in a
transgenic mouse model of AD "
SET Species = "10090"
SET MeSHDisease = "Alzheimer Disease"
a(CHEBI:pimozide) -> bp(GO:autophagy)
a(CHEBI:pimozide) -| p(MGI:Mapt,pmod(Ph))
UNSET Species
UNSET MeSHDisease

SET Evidence = "For instance, haloperidol occludes huntingtin aggregation"
a(CHEBI:haloperidol) -| a(HBP:"huntingtin aggregates")

SET Evidence = "Chronic clozapine treatment (20 mg/kg/day) reduces Abeta deposition"
a(CHEBI:clozapine) -| a(CHEBI:"amyloid-beta")
